Prostate cancer chemokine study withdrawn before starting
NCT ID NCT02869282
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study was designed to observe changes in certain immune system proteins (chemokines) in the blood and urine of men with prostate cancer over time. Researchers planned to collect samples from patients starting new treatments, but the study was withdrawn before any participants were enrolled. No results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Started
-
Jun 2011
- Finished
-
Dec 2016
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with a localized or metastatic prostate adenocarcinoma
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with a localized or metastatic prostate adenocarcinoma for which a new treatment will be implemented (hormone therapy for single biological relapse or relapses and metastatic hormone-sensitive) or chemotherapy (for biological relapses and / or metastatic hormone-resistant) * Patients with a detectable PSA (Prostate-Specific Antigen) * Patients who signed an informed consent * Patients over 18 years * Patients belonging to the social security scheme Exclusion Criteria: * Active Hepatitis B or C virus * HIV positive * Patients who have received prior chemotherapy * Patients with a second neoplasia treated in the last 5 years
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Prostate adenocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Bergonié
Bordeaux, 33076, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A scanner in the operating room could show surgeons exactly where prostate cancer remains
- New PET tracer aims to light up hidden cancer targets
- Can daily adaptive radiotherapy spare healthy tissue in prostate cancer?
- Can a radioactive tracer and MRI reveal prostate Cancer's true extent?
- Five-Fraction radiation plus hormone therapy tested against High-Risk prostate cancer
- Can a 10-Hour eating window fight cancer fatigue?